Literature DB >> 34088517

Positive attitudes toward clinical trials among military veterans leaves unanswered questions about poor trial accrual.

Grace Clarke Hillyer1, Yeun-Hee Anna Park2, Ta-Chueh Hsu Rosenberg3, Prabhjot Mundi2, Imtiaz Patel3, Susan E Bates4.   

Abstract

Participation in clinical trials is essential to bringing novel and innovative cancer treatments to the bedside but trials that specifically enroll Veterans are relatively few. Given the inherent differences between Veterans and the general United States population, we sought to investigate awareness of and attitudes toward clinical trials among Veterans diagnosed with cancer at a large, urban Veterans Administration Medical Center in Bronx, New York. The survey was administered in 2018-2019. Questions assessed sociodemographic characteristics, health literacy, and general attitudes about clinical trials. Based on key informant interviews, we also inquired about military-specific attitudes. Univariable analyses were conducted to evaluate differences in attitudes by age (<65 v ≥65 years) and race/ethnicity (non-Hispanic black v other). Of 115 Veterans approached, 67 (58.3%) completed the survey. Approximately 95% of participants were male, 59.7% were ≥65 years old, and 41.8% were non-Hispanic black. Only 58.2% reported knowing what a clinical trial is but 78.5% of Veterans stated that they trust doctors who do medical research and 87.5% reported they would strongly consider joining a trial if their VA primary care physician recommended it. Many stated that they would be part of a clinical trial if it would help fellow Veterans in the future (93.8%) and would help scientists learn how to treat other Veterans with the same disease (93.8%). Among non-Hispanic black participants, 62.5% agreed that the government has a history of using Veterans in experiments without their knowledge compared to 34.2% of Veterans of other race/ethnicity (P = 0.03). Clearly Veterans in our study were amenable to joining clinical trials. While many are aware of past misconduct in the treatment of military personnel in research, overall attitudes toward clinical trials were favorable and were especially positive when the possibility of improving cancer care for fellow Veterans was considered. In approaching Veterans regarding participation in a clinical trial we recommend education aligned with the literacy level of the Veteran, involvement of the VA primary care provider in clinical trial decisions, and awareness of a Veteran's altruism to help others.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Attitudes; Cancer; Clinical trials; Military personnel; Survey; Veterans

Mesh:

Year:  2021        PMID: 34088517      PMCID: PMC8530825          DOI: 10.1053/j.seminoncol.2021.04.001

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  33 in total

1.  Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation.

Authors:  Joseph M Unger; Dawn L Hershman; Mark E Fleury; Riha Vaidya
Journal:  JAMA Oncol       Date:  2019-03-01       Impact factor: 31.777

2.  The impact of socioeconomic status and race on trial participation for older women with breast cancer.

Authors:  Cary P Gross; Giovanni Filardo; Susan T Mayne; Harlan M Krumholz
Journal:  Cancer       Date:  2005-02-01       Impact factor: 6.860

3.  The eight-item modified Medical Outcomes Study Social Support Survey: psychometric evaluation showed excellent performance.

Authors:  André Moser; Andreas E Stuck; Rebecca A Silliman; Patricia A Ganz; Kerri M Clough-Gorr
Journal:  J Clin Epidemiol       Date:  2012-07-20       Impact factor: 6.437

4.  Measuring trust in medical researchers.

Authors:  Mark A Hall; Fabian Camacho; Janice S Lawlor; Venita Depuy; Jeremy Sugarman; Kevin Weinfurt
Journal:  Med Care       Date:  2006-11       Impact factor: 2.983

5.  VA Cancer Research: A Legacy and A Future.

Authors:  Susan E Bates; Michael J Kelley
Journal:  Semin Oncol       Date:  2019 Aug - Oct       Impact factor: 4.929

6.  Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients With Cancer.

Authors:  Lauren M Hamel; Louis A Penner; Terrance L Albrecht; Elisabeth Heath; Clement K Gwede; Susan Eggly
Journal:  Cancer Control       Date:  2016-10       Impact factor: 3.302

7.  A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies.

Authors:  Steven K Cheng; Mary S Dietrich; David M Dilts
Journal:  Clin Cancer Res       Date:  2010-11-09       Impact factor: 12.531

8.  Barriers to clinical trial participation as perceived by oncologists and patients.

Authors:  Neal J Meropol; Joanne S Buzaglo; Jennifer Millard; Nevena Damjanov; Suzanne M Miller; Caroline Ridgway; Eric A Ross; John D Sprandio; Perry Watts
Journal:  J Natl Compr Canc Netw       Date:  2007-09       Impact factor: 11.908

9.  Brief questions to identify patients with inadequate health literacy.

Authors:  Lisa D Chew; Katharine A Bradley; Edward J Boyko
Journal:  Fam Med       Date:  2004-09       Impact factor: 1.756

10.  The FACT-G7: a rapid version of the functional assessment of cancer therapy-general (FACT-G) for monitoring symptoms and concerns in oncology practice and research.

Authors:  B Yanez; T Pearman; C G Lis; J L Beaumont; D Cella
Journal:  Ann Oncol       Date:  2012-11-07       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.